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ABSTRACT 
A rapid, selective, precise and sensitive reverse phase high-performance liquid chromatography method was developed for the 
quantitative estimation of Levocetirizine Dihydrochloride (LD) in human plasma and pharmaceutical dosage form. Extraction of 
drug from plasma was done by employing optimized liquid-liquid extraction procedure. The sample was analyzed using acetonitrile: 
methanol: 20mM ammonium acetate buffer pH-5 (25:55:20 % v/v/v) as mobile phase. Chromatographic separation was achieved on 
Thermo C-18 column (4.6 x 250mm, 5μ particle size) as stationary phase using isocratic elution (at a flow rate of 1 ml/min). The 
peak was detected using UV-PDA detector set at 232 nm and the total time for a chromatographic separation was 8 min. The 
calibration curve obtained was linear (r2= 0.9998) over the concentration range of 2-10 μg/ml. Method was validated for precision, 
robustness and recovery. The limit of detection and limit of quantitation was 0.0057 and 0.174 µg/ml respectively. There was no 
significant difference between the amount of drug spiked in plasma and the amount recovered and plasma did not interfere in 
estimation. Thus, the proposed method is suitable for the analysis of LD in tablet dosage forms and human plasma. 
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INTRODUCTION 
Levocetirizine dihydrochloride (LD, Fig.1), chemically 
is (2-[4-[(R)-(4-chlorophenyl) henylmethyl]-1-
piperazinyl]ethoxy]-acetic acid dihydrochloride) is a 
third generation non sedative antihistamine
1
 and 
developed from the second generation antihistamine 
cetirizine. In many cases, the two racemic enantiomers 
differ in their pharmacokinetic and pharmacodynamic 
properties. Replacing existing recemates with single 
isomers has resulted in improved safety and/or efficacy 
profile of various recemates
2,3
. It works by blocking 
histamine receptors and polar in nature. LD has the 
advantages of higher efficacy, less side effects and 
longer duration over other antihistamines and has begun 
to replace cetirizine in clinical therapy stepwise. It has 
been chemically proved that the half dosage form of LD 
(2.5 mg) has comparable antihistaminic activity to 
normal amount (5.0 mg) of cetirizine in the treatment of 
allergic rhinitis and chronic idiopathic urticaria
4, 5
. LD is 
official in Indian Pharmacopoeia 
6
 and European 
Pharmacopoeia
7
 this describes acid-base titration with 
0.1 M NaOH in acetone/water medium. Literature 
survey revealed that LD has been reported to be 
determined by UV Spectrophotometry based on charge 
transfer reaction
8, 9
, LC-MS-MS
10,11
, RP-HPLC
12
 and by 
HPTLC
13
 in a variety of samples. LD in combination 
with a number of other drugs in tablet dosage form has 
been assayed by UV- spectrophotometry 
14,15
, ratio 
derivative spectrophotometry
16
, TLC-densitometry 
17,18
, 
Stability indicating
19
 and RP-HPLC 
20-25
. However there 
is no method available for estimation of LD in human 
plasma By RP-HPLC Therefore, an attempt was made to 
develop a new, rapid and sensitive method for the 
determination of LD in human plasma. To access the 
reproducibility and wide applicability of the developed 
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method, it was validated as per ICH norm, which is 
mandatory also
26, 27
. 
 
Figure 1: Chemical structure of levocetirizine 
dihydrochloride 
EXPERIMENTAL  
Materials 
The pure drug sample of LD (99.56%) was obtained as 
gift sample from Reddy’s Laboratory, Hyderabad. 
HPLC grade acetonitrile; methanol was purchased from 
Merck Ltd (Mumbai, India). All other chemicals and 
reagents used were of analytical grade. The human 
plasma was received from Peoples Hospital, Bhopal, 
MP, India. Triple distilled water was used throughout 
the process and prepared in-house; Liancet-L (5mg) 
Tablet was purchased from the local market.  
Equipments 
A high performance liquid chromatographic system 
from Waters comprising of manual injector, quaternary 
pump for constant flow and constant pressure delivery 
and Photodiode array detector connected to Ace 
software for controlling the instrumentation as well as 
processing the data generated was used. A thermo 
spectronic model of Lab India 3000 + UV/VIS 
Spectrophotometer with 1cm. matched quartz cells was 
used for determination of λmax.  
Chromatographic conditions 
The chromatographic analysis was performed by using a 
mobile phase of 20mM ammonium acetate buffer (pH 
5.0), methanol and acetonitrile (20:55:25 v/v). These 
were filtered through 0.45µ membrane filter and 
degassed by sonication before use. The mobile phase 
was pumped isocratically at a flow rate of 1.0ml/min 
during analysis at ambient temperature. The run time 
was set at 10 min and the volume of injection was 20µl 
and eluent was detected at 232 nm on a Thermo C-18 
column (4.6 x 250mm, 5μ particle size) Fig. 2.  
 
Figure 2: UV spectra of LD at 232 nm 
Selection of mobile phase 
Initially to estimate LD number of mobile phase in 
different ratio were tried. Taking into consideration the 
system suitability parameter like RT, Tailing factor, No. 
of theoretical plates and HETP, the mobile phase found 
to be most suitable for analysis was acetonitrile: 
methanol: 20 mM ammonium acetate buffer (pH 5.0) in 
the ratio of 25:55:20 v/v/v. The mobile phase was 
filtered through 0.45 filter paper to remove particulate 
matter and then degassed by sonication. Flow rate 
employed for analysis was 1.0 ml/min.        
Preparation of standard stock solution 
Accurately weigh and transfer 10mg of LD of working 
standard into 50ml clean dry volumetric flask add about 
40ml of diluents (Mobile Phase) and sonicate to dissolve 
it completely and make volume up to the mark with 
same solvent (Stock Solution). Further pipette 5ml of 
above stock solution in to a 10 ml volumetric flask and 
dilute up to the mark with diluents. Further pipette 0.2 to 
1.0 ml of above stock solution into a 10ml volumetric 
flask and dilute up to the mark with diluents. This gives 
the solutions of 2-10µg/ml for drug. 
Preparation of blank plasma 
To 1 ml of plasma, 4 ml of acetonitrile was added; the 
solution was mixed thoroughly and left to stand for 5 
min at room temperature. After 5 min the solution was 
centrifuged at 10000 rpm for 12 min at 4°C. The clear 
supernatant liquid was removed, filtered through 0.22 μ 
syringe filter and injected directly into HPLC system. 
Preparation of standard plasma stock solution 
To prepare calibration standards and quality control 
samples, appropriate quantities of the various diluted 
standard solutions added to blank plasma to obtain drugs 
in the concentrations range of 2-10µg/ml for LD. These 
were stored at –20°C and 20 µL volume of each sample 
was injected and chromatographed. 
Assay in formulations 
To determine the content of the drug in the 
formulations, twenty marketed tablets of Liancet-L 
(Azillian Healthcare Pvt. Ltd., Ahmedabad) were 
weighed and ground to a fine powder; amount equal to 
5 mg of LD was taken in 50-ml volumetric flask before 
50 ml diluents was added. The content of the flask was 
shaken for about 60 min. This solution was filtered 
through Whatman filter paper to separate out the 
insoluble excipients, and further dilutions were carried 
out to obtain the desired concentration. Final solutions 
were filtered through a 0.45-µm Millipore filter before 
injection into the HPLC. 
RESULT AND DISCUSSION 
Method validation 
The method was validated according to ICH guidelines 
such as linearity, precision, specificity, LOD, LOQ, 
accuracy and robustness. The linearity of this method 
was proved using linear correlation of the peak-area 
values and appropriate concentrations.  
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Linearity, limit of detection and quantification 
Under the previously described experimental conditions, 
linear correlation between the peak area and applied 
concentration was found in the concentration range 2-10 
µg/ml. The 
regression statistics are shown in Table 1. The LOD and 
LOQ at concentrations where the signal-to-noise ratios 
were equal to 3 and 10 respectively were determined to 
be 0.0057µg/ml and 0.174µg/ml for LD respectively. 
The correlation coefficient of this dependence was 
calculated to be 0.999 for LD. 
 
Table 1 Regression statistics and LOD and LOQ 
Drug Regression equation *r
2
 *LOD (µg/ml) *LOQ (µg/ml) 
Levocetirizine y = 396.6x +24.80 0.999 0.0057 0.174 
*Average of five determination 
 
Precision and robustness 
Precision of the methods was studied at three levels as at 
repeatability, intermediate precision (Day to Day and 
analyst to analyst) and reproducibility in synthetic 
samples using placebo mixtures. Mean ± SD and % 
relative standard deviation (RSD) values were used to 
express precision. As per ICH norms, small, but 
deliberate variations in concentration of the mobile 
phase were made to check the method’s capacity to 
remain unaffected. The ratio of mobile phase was 
change from, ACN: methanol: ammonium acetate buffer 
pH-5 (25:55:20 % V/V/V), to (25:54:21 % 
V/V/V).Results of precision and robustness are reported 
in Table 2. 
 
Table 2: Result of precision and robustness 
Validation Parameter Percentage Mean ± S.D*. (n=15) Percentage RSD* 
Repeatability               99.23±0.09 0.097 
Reproducibility               97.40±0.07 0.078 
      Intermediate precision 
Day to Day 97.24 ±0.17 0.179 
Analyst to Analyst 97.11±0.13 0.144 
Robustness* 96.87±0.10 0.110 
* Mean of fifteen determinations (3 replicates at 5 concentration level) 
 
Accuracy 
The accuracy of the proposed methods was assessed by 
recovery studies at three different levels i.e. 80%, 100% 
and 120%. The recovery studies were carried out by 
adding a definite concentration of standard drug (80%, 
100%, and 120%) to preanalyzed sample solutions. The 
resulting solutions were then re-analyzed by proposed 
methods. The value of mean recoveries was found to be 
in ranging from 97.76 to 99.88 for LD. Total amount of 
drug found and percentage recovery was calculated. 
Result of recovery studies are reported in Table 3. 
Table 3: Results from recovery studies of 
levocetirizine 
Recovery Level % Levocetirizine  
 % Mean±SD* % RSD* 
80 99.88±0.106 0.106 
100 97.76±1.317 1.347 
120 99.35±0.160 0.161 
*Average of five determination 
Specificity 
A representative chromatogram (Fig. 3) was generated 
to show that other components, which could be present 
in the sample matrix, are resolved from the parent 
analyte. No significant changes in retention times of the 
drugs in the presence and the absence of excipients 
clearly indicated the specificity of the method.  
Application in human Plasma 
It was observed after spiking the analyte in the plasma 
sample that there was no significant difference between 
the amount of drug spiked in plasma and the amount 
recovered. The recovery values (Table 4) in human 
plasma clearly indicate the applicability of the present 
method for the required purpose (Fig. 3). 
 
Table 4: Accuracy and precision in human plasma 
Analyte Spiked 
conc. 
(µg/ml) 
Precision 
(% RSD) 
Accuracy 
(%) 
Levocetirizine 2 0.92 99.60 
4 1.02 98.56 
6 1.50 98.45 
*Average of five determination
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    (A) 
 
    (B) 
Figure 3: Representative chromatogram of LD in formulation (A), in human plasma (B). 
 
CONCLUSION 
All the results obtained by HPLC studies, it was 
concluded that the present method was fast and easy to 
perform. The linearity range, precision, accuracy, 
robustness, LOD, LOQ and specificity were processed to 
establish the suitability of the method and the confirmed 
results were obtained. HPLC has several superiorities 
compared with UV spectrophotometry, such as smaller 
detection and quantification limits, small sample 
volumes and specificity. Thus, the developed HPLC 
method is rapid, reliable, cost-effective and can be 
proposed for routine analysis laboratories and quality 
control purposes and are very beneficial for 
pharmaceutical companies, clinicians and physicians and 
also can be beneficial for the studies of drug interaction 
with other combinations. 
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